13GD Runner: Exact Sciences Corp Has Another Bullish Trade, D. E. Shaw & Co Bought Stake!

13GD Runner: Exact Sciences Corp Has Another Bullish Trade, D. E. Shaw & Co Bought Stake!

The New D. E. Shaw & Co Holding in Exact Sciences Corp

D. E. Shaw & Co filed with the SEC SC 13G form for Exact Sciences Corp. The form can be accessed here: 000114420416127378. As reported in D. E. Shaw & Co’s form, the filler as of late owns 5% or 5,410,030 shares of the Health Care–company.

Exact Sciences Corp stake is a new one for the and it was filed because of activity on September 27, 2016. We feel this shows D. E. Shaw & Co’s positive view for the stock.

Exact Sciences Corp Institutional Sentiment

Latest Security and Exchange filings show 182 investors own Exact Sciences Corp. The institutional ownership in Q3 2015 is high, at 87.76% of the outstanding shares. This is increased by 7451954 the total institutional shares. 93706565 were the shares owned by these institutional investors. In total 22 funds opened new Exact Sciences Corp stakes, 83 increased stakes. There were 33 that closed positions and 52 reduced them.

Harvey Capital Management Inc is an institutional investor bullish on Exact Sciences Corp, owning 366250 shares as of Q3 2015 for 2.63% of its portfolio. J&P China Capital Management Company owns 1844727 shares or 6.90% of its portfolio. CA Primecap Management Company have 0.05% of their stock portfolio for 2736300 shares. Further, Signalpoint Asset Management Llc reported stake worth 0.14% of its US stock portfolio. The KS Mitchell Capital Management Co owns 117959 shares. Exact Sciences Corp is 0.74% of the manager’s US portfolio.

Business Profile

Exact Sciences Corporation is a molecular diagnostics company focused on the early detection and prevention of some forms of cancer. The Company’s product pipeline includes Lung Cancer Nodules, Pancreatic Cancer Screening, Esophageal Cancer Screening, Lung Cancer Pipeline, Pancreatic Cancer Pipeline and Esophageal Cancer Pipeline. It has developed a non invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a non invasive stool based deoxyribonucleic acid (DNA) screening test designed to detect DNA markers. In addition to DNA markers, its test includes a protein marker to detect blood in the stool, utilizing an antibody based fecal immunochemical test. The United States Food and Drug Administration (FDA) approved Cologuard for use as sDNA non-invasive colorectal cancer screening test. Cologuard is available through healthcare providers. It also focused on developing its pipeline for future products and services.

SEC Form 13G is required when the filer owns between (5% and 20%) of a company and plans to hold it only as a passive investor. In case the filler intend to exert control and the stake’s exceeds 20%, then 13D Form must be filed. These filings can NOT be a precursor to “change of control” events such as hostile takeovers, company breakups or others.

Insitutional Activity: The institutional sentiment increased to 1.42 in Q2 2016. Its up 0.70, from 0.72 in 2016Q1. The ratio improved, as 18 funds sold all EXACT Sciences Corporation shares owned while 41 reduced positions. 30 funds bought stakes while 54 increased positions. They now own 87.89 million shares or 11.45% more from 78.86 million shares in 2016Q1.

Massachusetts Financial Services Ma holds 0% or 449,506 shares in its portfolio. Metropolitan Life Insurance Ny holds 0.01% or 68,335 shares in its portfolio. Massmutual Trust Fsb Adv last reported 0% of its portfolio in the stock. Deutsche Fincl Bank Ag last reported 921,975 shares in the company. Moreover, Turner Investments Lp has 0.29% invested in EXACT Sciences Corporation (NASDAQ:EXAS) for 75,280 shares. Carl Domino holds 25,000 shares or 0.29% of its portfolio. The Wyoming-based Friess Ltd has invested 0.07% in EXACT Sciences Corporation (NASDAQ:EXAS). The California-based Palo Alto Invsts Lc has invested 0.37% in EXACT Sciences Corporation (NASDAQ:EXAS). Bank & Trust Of New York Mellon last reported 0% of its portfolio in the stock. Ladenburg Thalmann Financial Svcs Inc, a Florida-based fund reported 5,586 shares. Hightower Advsrs Ltd Com accumulated 295,564 shares or 0.05% of the stock. Mackenzie Finance accumulated 0.05% or 760,185 shares. Cam Group Hldg A S has invested 0.06% of its portfolio in EXACT Sciences Corporation (NASDAQ:EXAS). The Colorado-based Arrowpoint Asset Limited Company has invested 0.51% in EXACT Sciences Corporation (NASDAQ:EXAS). Focused Wealth Management Inc reported 175 shares or 0% of all its holdings.

Insider Transactions: Since July 25, 2016, the stock had 2 insider purchases, and 3 selling transactions for $97,947 net activity. COWARD D SCOTT also sold $30,584 worth of EXACT Sciences Corporation (NASDAQ:EXAS) on Friday, September 30. The insider ARORA MANEESH sold $109,060. $109,416 worth of EXACT Sciences Corporation (NASDAQ:EXAS) was sold by LIDGARD GRAHAM PETER. Shares for $90,500 were bought by Sterling Lionel on Thursday, September 1. Zanotti Katherine S bought $60,613 worth of EXACT Sciences Corporation (NASDAQ:EXAS) on Wednesday, August 3.

Analysts await EXACT Sciences Corporation (NASDAQ:EXAS) to report earnings on November, 3. They expect $-0.44 earnings per share, up 2.22% or $0.01 from last year’s $-0.45 per share. After $-0.46 actual earnings per share reported by EXACT Sciences Corporation for the previous quarter, Wall Street now forecasts -4.35% EPS growth.

The stock increased 0.31% or $0.06 during the last trading session, hitting $19.28. About 939,011 shares traded hands. EXACT Sciences Corporation (NASDAQ:EXAS) has risen 223.03% since March 4, 2016 and is uptrending. It has outperformed by 214.99% the S&P500.

Exact Sciences Corporation is a molecular diagnostics firm focused on the early detection and prevention of some forms of cancer. The company has a market cap of $2.10 billion. The Company’s product pipeline includes Lung Cancer Nodules, Pancreatic Cancer Screening, Esophageal Cancer Screening, Lung Cancer Pipeline, Pancreatic Cancer Pipeline and Esophageal Cancer Pipeline. It currently has negative earnings. It has developed a non invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer.

EXACT Sciences Corporation (NASDAQ:EXAS) Ratings Coverage

Out of 13 analysts covering EXACT Sciences (NASDAQ:EXAS), 5 rate it a “Buy”, 1 “Sell”, while 7 “Hold”. This means 38% are positive. $34 is the highest target while $4 is the lowest. The $12 average target is -37.76% below today’s ($19.28) stock price. EXACT Sciences has been the topic of 25 analyst reports since July 24, 2015 according to StockzIntelligence Inc. The rating was maintained by Jefferies with “Buy” on Thursday, February 25. Lake Street maintained EXACT Sciences Corporation (NASDAQ:EXAS) on Tuesday, November 24 with “Hold” rating. BTIG Research initiated the shares of EXAS in a report on Friday, December 18 with “Buy” rating. Wedbush maintained EXACT Sciences Corporation (NASDAQ:EXAS) rating on Thursday, October 8. Wedbush has “Neutral” rating and $7.0 price target. The firm has “Buy” rating given on Wednesday, October 7 by Mizuho. The stock of EXACT Sciences Corporation (NASDAQ:EXAS) has “Neutral” rating given on Wednesday, May 4 by Mizuho. The stock has “Buy” rating given by Jefferies on Wednesday, July 27. The stock of EXACT Sciences Corporation (NASDAQ:EXAS) earned “Buy” rating by Craig Hallum on Thursday, October 1. The firm has “Sell” rating by Empire given on Friday, February 26. The rating was maintained by Goldman Sachs with “Neutral” on Tuesday, October 6.

Another recent and important EXACT Sciences Corporation (NASDAQ:EXAS) news was published by Prnewswire.com which published an article titled: “Exact Sciences Announces Inclusion of Cologuard® in HEDIS Quality Measures” on October 03, 2016.

According to Zacks Investment Research, “EXACT Sciences Corporation uses applied genomics to develop effective, patient-friendly screening technologies for use in the detection of cancer. Certain of its technologies have been licensed to Laboratory Corporation of America Holdings for a stool-based DNA screening assay for colorectal cancer in the average-risk population. Colorectal cancer, which is the most deadly cancer among non-smokers, is generally curable if detected early. Despite the availability of colorectal cancer screening and diagnostic tests for more than twenty years, the rate of early detection of colorectal cancer remains low, and deaths from colorectal cancer remain high. EXACT Sciences believes its genomics-based technologies would help to enable detection of colorectal cancer so that more people can be effectively treated.”

EXAS Company Profile

Exact Sciences Corporation, incorporated on February 10, 1995, is a molecular diagnostics firm focused on the early detection and prevention of some forms of cancer. The Company’s product pipeline includes Lung Cancer Nodules, Pancreatic Cancer Screening, Esophageal Cancer Screening, Lung Cancer Pipeline, Pancreatic Cancer Pipeline and Esophageal Cancer Pipeline. The Firm has developed a non invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. The Company’s Cologuard test is a non invasive stool based deoxyribonucleic acid (DNA) (sDNA) screening test designed to detect DNA markers. In addition to DNA markers, its test includes a protein marker to detect blood in the stool, utilizing an antibody based fecal immunochemical test (FIT). The United States Food and Drug Administration (FDA) approved Cologuard for use as sDNA non-invasive colorectal cancer screening test. Cologuard is available through healthcare providers.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Related posts

Leave a Comment